EVT 302, 10 mg + placebo + Nicotine replacement therapy (NRT)
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Smoking Cessation
Conditions
Smoking Cessation
Trial Timeline
Feb 1, 2008 → May 1, 2008
NCT ID
NCT00622752About EVT 302, 10 mg + placebo + Nicotine replacement therapy (NRT)
EVT 302, 10 mg + placebo + Nicotine replacement therapy (NRT) is a phase 2 stage product being developed by Evotec for Smoking Cessation. The current trial status is completed. This product is registered under clinical trial identifier NCT00622752. Target conditions include Smoking Cessation.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00622752 | Phase 2 | Completed |
Competing Products
20 competing products in Smoking Cessation